Russian Drugmaker Granted License to Produce Celgene Copycat [Fortune]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Fortune
For the first time ever, a Russian pharmaceutical company got a license to produce an analog of a Western drug in Russia , reports The Pharma Letter . U.S.-based Celgene’s Revlimid drug will now be produced by Russian drugmaker Nativa, given the compulsory license issued by the Moscow Arbitration Court. Revlimid, scientific name lenalidomide, is an antitumor immunomodulator used to treat blood cancer. In 2017, the drug generated $8.2 billion of sales for Celgene, according to STAT. In March of 2017, the biopharmaceutical company filed a suit against Russian Nativa in an effort to halt their production and sale of the drug. The FDA shamed Celgene in May for blocking the production of several cheap generic alternatives to their drugs, including Revlimid. Nativa filed a counterclaim, asking the court to grant the compulsory license for the Russian market. This deal means Nativa can continue producing the drug, but it owes royalties to Celgene. It said that the
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMYPR Newswire
- Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts [Yahoo! Finance]Yahoo! Finance
- Overhaul Sets New Standard in OTR Compliance with Launch of CompliTrack [Yahoo! Finance]Yahoo! Finance
- Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research [Yahoo! Finance]Yahoo! Finance
- 20 Countries with the Highest Heart Disease Deaths Per Capita [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 3/18/24 - Form 8-K
- 3/18/24 - Form PRE
- 3/18/24 - Form 8-K
- BMY's page on the SEC website